Announcements Trials
Browse Landscape

Phase

Phase 2 27Phase 1/2 3Phase 1 3

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 7OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 1

Interventions

Cyclophosphamide 250Radiotherapy 172pembrolizumab 154Carboplatin 146Gemcitabine 139Nivolumab 135Paclitaxel 129Dexamethasone 118Cisplatin 118fludarabine 115Rituximab 104Lenalidomide 103Bevacizumab 99Docetaxel 97Capecitabine 97fludarabine phosphate 92Temozolomide 89Cytarabine 89Oxaliplatin 87Etoposide 82Filgrastim 77Irinotecan 73Doxorubicin 73venetoclax 70Peripheral Blood Stem Cell Transplantation 68Fluorouracil 68Radiosurgery 66Melphalan 66Everolimus 66Bortezomib 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × glofitamab × Clear all
NCT05861050 2026-02-19

Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

City of Hope Medical Center

Phase 1/2 Recruiting
50 enrolled
Lymphoid

Lymphoma, Mantle-Cell

NCT06357676 2026-01-30

Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial

OHSU Knight Cancer Institute

Phase 1/2 Recruiting
27 enrolled
Lymphoid

Lymphoma, Mantle-Cell

NCT04914741 2024-08-12

COALITION

Peter MacCallum Cancer Centre, Australia

Phase 1/2 Active not recruiting
80 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡